Oral Prednisone for Alopecia Areata

Prednisone is a systemic corticosteroid that has been used for decades to suppress inflammation and immune activity in a wide range of medical conditions. In alopecia areata, its purpose is to interrupt the autoimmune activity directed against susceptible hair follicles and, in selected patients, rapidly bring active disease under control.

Oral prednisone can produce meaningful hair regrowth, particularly when alopecia areata is recent, active and progressing rapidly. Its major limitation is not whether corticosteroids can suppress the disease. They clearly can. The problem is that the benefit is often treatment dependent. Hair loss can resume as the dose is reduced or after treatment is stopped, while the adverse effects of systemic corticosteroids generally make prolonged maintenance therapy inappropriate for a hair loss disorder.

For that reason, oral prednisone should not be viewed as a routine long term hair growth medication. Its most rational role is generally as a time limited systemic treatment for selected patients with rapidly progressive, widespread or otherwise significant alopecia areata.

Systemic corticosteroids remain supported by current international alopecia areata guidelines. Their role has changed with the availability of FDA approved JAK inhibitors, but they have not become obsolete. Prednisone and related corticosteroids can still be useful when rapid short term suppression of highly active disease is clinically appropriate.

What Is Prednisone?

Prednisone is a synthetic glucocorticoid. After it is taken orally, prednisone is converted primarily in the liver into prednisolone, the biologically active corticosteroid that produces most of its anti inflammatory and immunosuppressive effects.

Corticosteroids influence a very large number of immune and metabolic pathways. They reduce production of inflammatory signaling molecules, alter immune cell activity and suppress immune responses that contribute to autoimmune disease.

This broad activity explains both their effectiveness and their limitations. Prednisone does not selectively target one pathway involved in alopecia areata. It suppresses immune activity throughout the body.

That can quickly reduce autoimmune inflammation, but it can also affect blood sugar, blood pressure, mood, sleep, infection resistance, bone metabolism, the adrenal glands and numerous other systems.

Prednisone Versus Prednisolone

Patients researching alopecia areata will encounter both prednisone and prednisolone in the medical literature.

Prednisone is commonly prescribed in the United States. Prednisolone is used more commonly in many other countries and appears frequently in alopecia areata studies and international treatment guidelines.

The medications are closely related. Prednisone is converted in the body into active prednisolone. This is why evidence involving prednisolone is relevant when discussing systemic corticosteroid treatment for alopecia areata, although the names should not simply be used interchangeably when describing a specific clinical trial or prescription.

The current British Association of Dermatologists guideline, for example, discusses oral prednisolone, while older American research specifically evaluated prednisone.

Is Oral Prednisone FDA Approved for Alopecia Areata?

No. Prednisone is FDA approved and widely used for numerous inflammatory, allergic, autoimmune and other medical conditions, but there is no FDA approved prednisone indication specifically for alopecia areata.

Its use for alopecia areata is therefore off label.

Off label prescribing is common in medicine and does not mean that a treatment is experimental or inappropriate. It means that the FDA has not reviewed and approved a specific prednisone regimen for this particular condition.

There is consequently no FDA established prednisone dose, treatment duration or tapering schedule specifically for alopecia areata.

Why Is Prednisone Used for Alopecia Areata?

Alopecia areata is an autoimmune form of nonscarring hair loss. Immune activity develops around susceptible follicles and interferes with their normal growth cycle. In active disease, hairs may shed rapidly while follicles enter a nonproductive state.

Prednisone can suppress that immune activity throughout the body. When the autoimmune attack is brought under sufficient control and the follicles remain capable of producing hair, shedding may slow and hair growth can resume.

The effect can sometimes be relatively rapid compared with treatments that require months before meaningful disease control becomes apparent.

This makes systemic corticosteroids particularly relevant when the immediate clinical problem is not simply an established bald patch but rapidly advancing autoimmune hair loss.

Who Is Most Likely to Be Considered for Oral Prednisone?

Current guidelines support considering systemic corticosteroids in patients with rapidly progressive alopecia areata and in selected patients with moderate to severe disease.

A patient who is losing substantial amounts of hair over a matter of weeks may represent a very different treatment situation from someone who has had one stable patch for several months. In rapidly progressive disease, short term systemic corticosteroid treatment may help interrupt the active immune process before additional scalp involvement occurs.

Prednisone may also be considered when the distribution of disease makes local therapy impractical. Injecting a few discrete alopecia areata patches with triamcinolone can make sense. Attempting to inject much of the scalp while hair loss is continuing to spread may not.

Disease extent alone should not determine treatment. Speed of progression, eyebrow and eyelash involvement, previous episodes, duration of the current episode, treatment history, medical risk and psychological impact all contribute to the decision.

Should Oral Prednisone Be Used for One or Two Small Patches?

Usually not as the first approach.

Limited patchy alopecia areata can often be treated with intralesional triamcinolone or potent topical corticosteroids without exposing the entire body to systemic corticosteroid effects.

Systemic treatment becomes easier to justify as disease becomes more extensive, difficult to treat locally or rapidly progressive.

This distinction matters because prednisone can be very effective at suppressing inflammation, but the medical cost of systemic exposure is considerably greater than that of appropriately administered local therapy.

How Effective Is Oral Prednisone for Alopecia Areata?

Systemic corticosteroids can produce hair regrowth, but the evidence base is considerably older and more heterogeneous than the modern Phase III programs used to evaluate JAK inhibitors.

Studies have used different corticosteroids, different doses, daily treatment, weekly pulses, monthly pulses, intravenous therapy and different definitions of successful regrowth. Many studies were small and lacked placebo controls.

The consistent finding is that corticosteroids can suppress active alopecia areata and induce regrowth in a meaningful proportion of patients. The equally consistent problem is that relapse is common and durable control after corticosteroid withdrawal is unpredictable.

This is why systemic corticosteroids have remained clinically useful for decades without becoming an ideal long term treatment.

What Did the Classic Prednisone Study Show?

An important American study published in 1992 evaluated a six week tapering course of oral prednisone in patients with alopecia areata.

At the end of six weeks, approximately 47 percent of patients in the controlled portion of the study had achieved more than 25 percent terminal hair regrowth. In a separate open treatment group, approximately 30 percent achieved that level of improvement.

Weight gain and mood changes or emotional lability were among the primary prednisone related adverse effects.

The study also examined topical minoxidil after prednisone treatment. Some patients receiving minoxidil maintained more of the corticosteroid induced regrowth than patients receiving vehicle alone, although the study was small and involved 2 percent minoxidil applied more frequently than is commonly used today.

The important historical lesson was already apparent more than three decades ago: systemic corticosteroids could stimulate substantial regrowth, but maintaining that response after the systemic steroid was withdrawn was considerably more difficult.

What Did the Placebo Controlled Pulse Study Show?

A later randomized placebo controlled study evaluated 43 patients with extensive alopecia areata. Twenty three patients were assigned to prednisolone 200 mg once weekly for three months, while 20 received placebo.

Among the 20 prednisolone treated patients who completed the study, 8, or 40 percent, achieved more than 30 percent hair regrowth. No placebo treated patient achieved comparable significant regrowth. Only two steroid treated patients achieved greater than 60 percent regrowth.

Two of the eight responders relapsed during the three month observation period after treatment.

This trial demonstrated biological and clinical activity with intermittent oral corticosteroid treatment, but it was small. It did not establish that a 200 mg weekly pulse is the optimal regimen, nor did it solve the problem of relapse after treatment.

What Does the Newer Methotrexate Plus Prednisone Trial Show?

A more contemporary randomized double blind trial published in 2023 studied adults with chronic alopecia totalis or alopecia universalis, including patients with longstanding and difficult to treat disease.

The study initially evaluated methotrexate against placebo. Patients who did not achieve adequate regrowth were subsequently evaluated with methotrexate combined with low dose prednisone or methotrexate with placebo.

Among 35 patients receiving methotrexate plus prednisone, 7, or 20 percent, achieved complete or almost complete hair regrowth. In the subgroup that had received methotrexate for 12 months followed by six months of added prednisone, 5 of 16 patients, approximately 31 percent, achieved complete or nearly complete regrowth.

This study does not establish the effectiveness of prednisone alone because prednisone was combined with methotrexate. It does demonstrate that significant regrowth can sometimes be achieved even in chronic alopecia totalis or universalis when corticosteroid treatment is incorporated into a longer term steroid sparing strategy.

What Is Corticosteroid Pulse Therapy?

Pulse therapy refers to giving relatively large doses of corticosteroid intermittently rather than exposing the patient to continuous daily treatment for an extended period.

Published alopecia areata protocols have varied enormously. Studies have examined weekly oral pulses, monthly oral pulses, several consecutive days of treatment at intervals, intravenous methylprednisolone and other corticosteroid regimens.

The purpose of pulse treatment is to obtain substantial immunosuppressive activity while reducing cumulative corticosteroid exposure and allowing drug free periods between treatments.

The accumulated pulse therapy literature confirms that meaningful regrowth can occur, but studies are highly heterogeneous and do not provide one reliable response percentage that can be applied to every patient.

There is no universally accepted pulse regimen for alopecia areata. Consumers may encounter very specific protocols online and assume that one schedule has been established as the standard. It has not.

Is Daily Prednisone or Pulse Therapy Better?

There is no definitive head to head evidence establishing one systemic corticosteroid regimen as universally superior.

Current guidelines actually illustrate the uncertainty.

The British Association of Dermatologists living guideline suggests that an oral corticosteroid course such as prednisolone approximately 0.5 mg per kilogram per day tapered over six to twelve weeks can be considered for rapidly progressive or moderate to severe alopecia areata.

The 2026 German S3 guideline takes a somewhat different approach and recommends that, when systemic corticosteroids are used for alopecia areata, treatment generally be given in pulsed doses rather than continuously.

Other expert groups have used daily courses, intermittent pulses or both.

The absence of one universal regimen is not evidence that corticosteroids do not work. It reflects the difficulty of balancing rapid immune suppression against cumulative toxicity and relapse.

Does a Higher Prednisone Dose Work Better?

There is no evidence supporting a simple rule that more corticosteroid produces better long term hair outcomes.

Higher systemic exposure can produce stronger immunosuppression, but it also increases the likelihood of adverse effects. Alopecia areata studies have used very different doses, making direct comparisons difficult.

A treatment that produces dramatic regrowth only while a patient remains on an exposure that cannot safely be maintained is not necessarily a better treatment.

The objective should be adequate short term disease control using an exposure and duration appropriate for the individual clinical situation, followed by a realistic strategy for maintaining control without prolonged high dose systemic corticosteroid use.

Who Tends to Respond Better to Corticosteroid Pulse Therapy?

Reviews of the pulse corticosteroid literature suggest that patients with more recent onset and actively progressive alopecia areata may respond better than patients with very longstanding disease.

Multifocal patchy alopecia areata has generally produced better results than longstanding alopecia totalis or alopecia universalis in older corticosteroid studies. Shorter disease duration has also been associated with better outcomes in several reports.

These are population trends, not absolute rules.

A patient with severe or longstanding disease can respond, while someone with recent disease may not. These characteristics should help inform expectations rather than serve as rigid criteria for withholding treatment.

How Quickly Can Prednisone Work?

Systemic corticosteroids can sometimes slow active shedding relatively quickly because immune suppression begins well before new hair becomes cosmetically visible.

Hair growth itself still requires time. Even after autoimmune activity is controlled, follicles must reenter productive growth and generate hair of sufficient length and diameter to become visible.

In pulse therapy studies, meaningful regrowth has often appeared over the first several months rather than within days.

A rapid reduction in disease activity and visible hair regrowth are therefore related but not identical treatment outcomes.

What Happens When Prednisone Is Reduced?

This is one of the most important issues with systemic corticosteroid treatment for alopecia areata.

Some patients maintain regrowth as the dose is reduced. Others begin losing hair again during dose reduction or after treatment is stopped.

Current guidelines explicitly acknowledge that some patients cannot maintain their response once systemic corticosteroid exposure declines.

Increasing the prednisone dose again may restore disease control, but repeatedly doing so can create a cycle in which hair is maintained only through continued systemic corticosteroid exposure.

That is generally not an acceptable long term treatment strategy for alopecia areata.

Why Is Prednisone Sometimes Tapered?

There are several different reasons a physician may gradually reduce prednisone, and they should not be confused.

One is control of the underlying alopecia areata. A gradual reduction may allow physicians to determine whether the disease remains controlled as systemic immunosuppression decreases and whether another treatment is maintaining the response.

Another issue is adrenal physiology. Systemic glucocorticoids can suppress the body’s natural production of cortisol through the hypothalamic pituitary adrenal, or HPA, axis. The risk depends on dose, duration and repeated exposure.

Current endocrine guidance indicates that systemic glucocorticoid treatment lasting less than approximately three to four weeks generally does not require tapering specifically to protect against adrenal insufficiency, regardless of dose. The risk of HPA axis suppression becomes more relevant when treatment extends beyond approximately three to four weeks at doses above normal physiologic corticosteroid exposure.

This distinction is particularly relevant to alopecia areata because guideline supported daily corticosteroid regimens may last six to twelve weeks.

Patients receiving a prescribed taper should follow that schedule rather than independently changing or stopping prednisone.

Alopecia Relapse, Steroid Withdrawal and Adrenal Insufficiency Are Not the Same Thing

Hair loss returning during a prednisone taper does not necessarily mean that a patient’s adrenal glands are failing. It may simply mean that the autoimmune disease is becoming active again as immunosuppression decreases.

Glucocorticoid withdrawal syndrome is another distinct phenomenon. During dose reduction, some patients can experience fatigue, weakness, muscle or joint discomfort, mood changes and other symptoms even when they are not experiencing true adrenal crisis.

Adrenal insufficiency occurs when the body cannot produce adequate cortisol after significant HPA axis suppression. Symptoms can include profound fatigue, weakness, nausea, vomiting, low blood pressure and other potentially serious problems.

These three issues can overlap clinically, but they are not interchangeable.

Does Tapering Prevent Alopecia Areata From Returning?

Not necessarily.

Tapering can be medically important, but it does not eliminate the underlying autoimmune susceptibility responsible for alopecia areata.

Hair loss can recur despite a carefully managed taper.

This distinction is important because a patient may assume that relapse means the taper was performed incorrectly. In many cases, relapse reflects the fact that prednisone was suppressing an ongoing autoimmune process that became active again once systemic immunosuppression declined.

Can Prednisone Cure Alopecia Areata?

No.

Prednisone can suppress the immune response responsible for active disease and may allow substantial hair regrowth. It does not permanently remove the biological tendency to develop alopecia areata.

Some patients may enter a prolonged remission after treatment. Others relapse quickly. Still others experience recurrent episodes years later.

Treatment success should therefore be described as control of the current episode and restoration of hair growth rather than permanent elimination of the disease.

Can Another Treatment Help Maintain the Response?

Possibly.

The problem of post corticosteroid relapse has led clinicians to use other treatments during or after the corticosteroid course.

Current British guidance suggests considering concurrent topical therapy such as a potent topical corticosteroid or topical minoxidil in moderate to severe disease, with the goal of maintaining response as the systemic corticosteroid is tapered.

Steroid sparing systemic medications such as methotrexate, cyclosporine and azathioprine have also been used in selected patients when longer term systemic disease control is necessary.

The 2023 randomized methotrexate study provides modern controlled evidence supporting the principle that prednisone can sometimes contribute meaningful additional regrowth when incorporated into a steroid sparing regimen in severe chronic disease.

That does not mean methotrexate plus prednisone should automatically be used for severe alopecia areata. It demonstrates why systemic corticosteroids are often more rational as one part of a transition strategy than as indefinite maintenance therapy.

How Have JAK Inhibitors Changed the Role of Prednisone?

The treatment landscape is very different from the era when prednisone was one of the few available systemic options.

Baricitinib and deuruxolitinib are FDA approved for adults with severe alopecia areata. Ritlecitinib is FDA approved for adults and adolescents age 12 and older.

These medications can provide sustained systemic disease control without relying on chronic corticosteroid exposure, although they have their own important risks and monitoring requirements.

Prednisone can still have an important role when disease is progressing rapidly and immediate broad immunosuppression is clinically useful. It may provide short term control while the longer term treatment plan is being established.

This should not be interpreted to mean that routine concurrent treatment with prednisone and a JAK inhibitor has been established as superior. Evidence for that specific combination remains limited.

What prednisone should generally not become is indefinite maintenance therapy simply because hair begins falling again whenever the dose is reduced.

How Should Treatment Response Be Measured?

Systemic corticosteroid treatment should not be judged solely by memory or by whether a patient feels that the hair looks somewhat better.

Standardized photographs taken under consistent lighting and positioning can document whether areas of hair loss are actually shrinking or filling in.

For patients with more extensive scalp disease, the Severity of Alopecia Tool, or SALT score, can provide a standardized measure of scalp hair loss over time.

Objective documentation is particularly useful with systemic corticosteroids because significant medical exposure should not be continued without evidence that the disease is actually responding.

What Are the Most Common Short Term Side Effects?

Even a relatively short corticosteroid course can produce noticeable adverse effects. These can include:

• Increased appetite
• Weight gain
• Fluid retention
• Facial puffiness
• Insomnia
• Restlessness
• Irritability or mood changes
• Increased energy or agitation
• Indigestion or stomach irritation
• Increased blood pressure
• Increased blood sugar
• Acne or other skin changes

The likelihood and severity depend on dose, duration, individual susceptibility and other medical conditions.

Patients sometimes assume that a six or eight week corticosteroid course is too short to cause meaningful systemic effects. That is not necessarily true, particularly at the doses used to suppress autoimmune disease.

Large observational studies have also associated even short systemic corticosteroid courses with small increases in serious events such as infection, blood clots and fractures. Those studies cannot prove that corticosteroids caused every event, but they reinforce that short term systemic treatment should not be considered medically trivial.

Can Prednisone Affect Mood or Mental Health?

Yes.

Systemic corticosteroids can produce insomnia, anxiety, irritability, emotional lability, euphoria and mood changes. Less commonly, more severe psychiatric reactions including depression, mania, confusion or psychosis can occur.

These effects can appear relatively early in treatment and are not limited to patients with a previous psychiatric diagnosis.

Patients and family members sometimes recognize behavioral or sleep changes before the person taking prednisone does.

Significant mood disturbance, severe agitation, unusual behavior, suicidal thinking, hallucinations or other serious psychiatric symptoms require prompt medical attention.

Can Prednisone Raise Blood Sugar?

Yes.

Glucocorticoids increase glucose production and can reduce insulin sensitivity. Blood sugar can therefore rise during systemic corticosteroid treatment.

This can be particularly important in people with diabetes or prediabetes, but substantial glucose elevations can occasionally reveal previously unrecognized metabolic disease.

Patients with diabetes may require more frequent glucose monitoring and temporary changes in medication while receiving systemic corticosteroids.

Can Prednisone Raise Blood Pressure or Cause Fluid Retention?

It can.

Prednisone can promote sodium and fluid retention and can contribute to increased blood pressure, swelling and weight gain. The magnitude varies among patients and depends partly on dose and duration.

Systemic corticosteroids can also contribute to potassium loss and hypokalemia in susceptible patients, particularly when combined with other medications that lower potassium.

People with hypertension, heart disease, kidney disease, electrolyte problems or a tendency toward edema deserve additional consideration before systemic corticosteroid treatment.

A rapid increase on the scale during prednisone treatment may reflect fluid retention and increased appetite rather than an actual increase in body fat alone.

Does Prednisone Increase the Risk of Infection?

Yes.

Prednisone suppresses immune function and can increase susceptibility to bacterial, viral, fungal and other infections. It can also reduce inflammatory signs that normally make an infection obvious.

The degree of risk depends greatly on dose, duration, cumulative exposure and the patient’s underlying health.

Before meaningful systemic corticosteroid treatment, the physician should consider active infection and relevant latent infection risks based on the patient’s medical history, exposures, geographic history and anticipated treatment.

Prednisone should not be viewed as simply a powerful hair medication. It is systemic immunosuppressive therapy.

What About Strongyloides Infection?

Strongyloides is a parasitic infection that deserves particular attention before systemic corticosteroid treatment in patients with relevant epidemiologic risk.

Some people can carry Strongyloides for years without obvious symptoms. Corticosteroid induced immune suppression can allow the parasite to multiply dramatically, causing hyperinfection or disseminated disease that can become life threatening.

This does not mean every person receiving prednisone for alopecia areata requires routine parasite testing.

Patients who have lived in or traveled extensively through areas where Strongyloides is endemic, have unexplained eosinophilia or have other relevant exposure history should make sure the prescribing physician is aware of it before significant systemic corticosteroid exposure.

What About Vaccines?

Vaccination decisions can be affected by immunosuppressive corticosteroid treatment.

Current CDC guidance generally considers systemic prednisone exposure of at least 20 mg daily, or at least 2 mg per kilogram per day, for 14 consecutive days or longer sufficiently immunosuppressive to raise concern about live vaccines.

Live vaccines are generally deferred during that level of systemic corticosteroid treatment and for at least one month after high dose corticosteroid therapy is discontinued.

Lower doses and short courses lasting less than 14 days do not carry the same restrictions.

Nonlive vaccines are not dangerous because of corticosteroid immunosuppression, but immune responses can sometimes be reduced during significant systemic treatment.

Patients who know they need vaccination or who are planning international travel should discuss timing with the prescribing physician.

Can Prednisone Affect the Adrenal Glands?

Yes.

External corticosteroids tell the body that additional cortisol production is not needed. With sufficient exposure, the HPA axis can reduce its own cortisol production.

The risk becomes more important with longer treatment, higher cumulative exposure and repeated systemic corticosteroid courses.

For courses lasting less than approximately three to four weeks, current endocrine guidance generally considers clinically significant HPA axis suppression unlikely enough that an adrenal taper is not routinely required.

Alopecia areata regimens lasting six to twelve weeks fall outside that short course category and deserve more careful tapering and clinical consideration.

Repeated corticosteroid courses can also contribute to cumulative adrenal suppression even when individual courses are separated in time.

What Are the Risks of Longer Term Prednisone Use?

The risk profile becomes considerably more concerning as exposure becomes longer or repeated.

Potential complications include osteoporosis and fractures, muscle weakness, adrenal suppression, hypertension, diabetes, cataracts, glaucoma, increased infection risk, skin thinning, easy bruising, impaired wound healing, weight gain and Cushingoid physical changes.

Corticosteroids can also contribute to loss of muscle mass and changes in fat distribution.

Rare but serious complications such as osteonecrosis, including avascular necrosis of the hip, have been associated with systemic corticosteroid exposure.

These risks are central to understanding why prednisone can be valuable for rapidly active alopecia areata yet inappropriate as indefinite maintenance treatment.

What About Bone Health?

Systemic corticosteroids can reduce bone formation, increase bone breakdown and interfere with calcium metabolism.

The concern increases with prolonged or repeated treatment, higher cumulative exposure, older age, menopause, low body weight, smoking and other osteoporosis risk factors.

A short isolated course does not carry the same skeletal risk as chronic prednisone treatment, but repeated courses should not be considered medically invisible.

Patients requiring substantial or recurrent systemic corticosteroid therapy may need individualized assessment of calcium and vitamin D intake, bone health and osteoporosis prevention.

Can Prednisone Affect the Eyes?

Yes.

Systemic corticosteroids can increase intraocular pressure and contribute to glaucoma. Longer exposure can also promote posterior subcapsular cataracts.

Corticosteroids can additionally worsen or facilitate certain ocular infections.

Current prescribing information recommends monitoring intraocular pressure when systemic corticosteroid treatment is continued for more than approximately six weeks.

That threshold is particularly relevant in alopecia areata because some daily corticosteroid regimens extend from six to twelve weeks.

Patients with glaucoma, significant eye disease or recurrent corticosteroid exposure should make sure the prescribing physician knows their history.

Can Prednisone Cause Stomach Problems?

Prednisone can cause indigestion, stomach irritation and other gastrointestinal symptoms. Peptic ulceration and gastrointestinal bleeding or perforation are much less common but potentially serious complications.

Risk can increase when systemic corticosteroids are combined with certain other medications, particularly nonsteroidal anti inflammatory drugs.

Prednisone is often taken with food to reduce stomach irritation, but patients should follow the instructions given with their own prescription.

New severe abdominal pain, gastrointestinal bleeding or black stools require medical evaluation rather than being dismissed as an expected corticosteroid side effect.

Are There Important Drug Interactions?

Yes.

Systemic corticosteroids can interact with medications that affect blood sugar, blood pressure, potassium, blood clotting, immune function and corticosteroid metabolism.

Nonsteroidal anti inflammatory drugs and aspirin can increase gastrointestinal risk. Diabetes medications may require adjustment because prednisone can raise glucose. Prednisone can alter the response to warfarin and other anticoagulation, so additional monitoring may sometimes be required.

Medications that strongly inhibit or induce CYP3A4 can change systemic corticosteroid exposure. Cyclosporine and corticosteroids can also affect one another’s metabolism and toxicity.

Potassium depleting medications can compound corticosteroid related potassium loss.

The medication list should include prescription drugs, over the counter products and supplements before systemic corticosteroid treatment begins.

Can Prednisone Be Used During Pregnancy?

Systemic corticosteroids are sometimes medically necessary during pregnancy for serious maternal conditions, so pregnancy is not an absolute prohibition on prednisone use.

Current human evidence is more reassuring than older concerns sometimes suggest. Prednisone and prednisolone are not expected to greatly increase the overall risk of major birth defects. Older studies suggested a possible small increase in cleft lip or palate after first trimester exposure, but newer studies have not confirmed a clear association.

Longer term oral corticosteroid exposure during pregnancy has been associated with outcomes such as preterm delivery and lower birth weight, although it is difficult to separate medication effects from the underlying medical conditions requiring treatment.

Alopecia areata treatment is generally elective from the standpoint of maternal survival. For that reason, the threshold for exposing a pregnant patient to systemic corticosteroids solely for hair loss should remain appropriately high.

A patient who is pregnant or planning pregnancy should discuss the treatment strategy with the prescribing physician before beginning or continuing prednisone.

Can Prednisone Be Used While Breastfeeding?

Prednisone and prednisolone pass into breast milk in very small amounts.

Available human data are generally reassuring, and LactMed reports no adverse effects in breastfed infants from maternal corticosteroid use in the available literature.

It is sometimes recommended that women wait four hours after taking prednisone before breastfeeding. Current LactMed guidance notes that this is generally unnecessary because milk concentrations are very low.

Medium to large systemic corticosteroid doses may temporarily reduce milk production in some women.

A breastfeeding patient should still discuss the specific dose and treatment schedule with her physician, particularly when high dose or repeated pulse therapy is being considered.

Can Children Receive Oral Corticosteroids for Alopecia Areata?

Sometimes, but systemic corticosteroids should be used selectively in children and adolescents.

The 2026 German S3 guideline recommends against systemic corticosteroids for children and adolescents with mild or moderate alopecia areata but allows them to be considered in severe or very severe disease.

This distinction makes clinical sense. A child with one or several limited patches should not be exposed to systemic corticosteroid risk simply because prednisone can suppress alopecia areata.

For severe or rapidly progressive disease, systemic corticosteroids can be considered under specialist supervision. In adolescents age 12 and older, ritlecitinib now provides an FDA approved systemic alternative for severe alopecia areata.

Children also have additional concerns involving growth, bone development, adrenal suppression, infection risk and the cumulative consequences of repeated corticosteroid exposure.

Does Prednisone Work for Alopecia Totalis or Alopecia Universalis?

Some patients with alopecia totalis or alopecia universalis have responded to systemic corticosteroids.

Older pulse therapy studies generally found less consistent and less durable responses in longstanding totalis or universalis than in recent onset multifocal patchy alopecia areata.

That does not mean severe longstanding disease cannot respond.

The 2023 randomized methotrexate study showed that some adults with chronic alopecia totalis or universalis achieved complete or nearly complete regrowth after low dose prednisone was added to methotrexate.

The larger practical problem remains maintenance. Even if systemic corticosteroids produce substantial regrowth, maintaining that response through chronic prednisone exposure may create an unacceptable long term risk.

The availability of FDA approved JAK inhibitors has become particularly important for this population.

Is Prednisone Used for Male or Female Pattern Hair Loss?

No.

Ordinary male androgenetic alopecia and female pattern hair loss are not autoimmune diseases treated by systemic corticosteroid suppression.

Prednisone does not address the underlying androgen related follicular miniaturization responsible for common pattern hair loss.

Using systemic prednisone simply because a patient is shedding or thinning without first establishing the diagnosis could expose the patient to substantial unnecessary risk.

What About Telogen Effluvium?

Prednisone is not a routine treatment for ordinary telogen effluvium.

Diffuse shedding caused by illness, nutritional problems, medication changes, hormonal changes, major physiological stress or other telogen effluvium triggers generally requires identification and management of the underlying cause.

Diffuse alopecia areata can sometimes resemble telogen effluvium, which is one reason the diagnosis matters before systemic corticosteroid treatment is started.

A dramatic shedding complaint by itself is not sufficient reason to prescribe prednisone.

What Should Be Evaluated Before Starting Oral Prednisone for Alopecia Areata?

The first priority is confirming the diagnosis and determining whether systemic therapy is justified.

The physician should assess the extent and speed of hair loss, duration of the current episode, eyebrow and eyelash involvement, previous alopecia areata episodes, prior treatments and objective evidence that disease is active. Standardized photographs and, when appropriate, SALT scoring can provide a useful baseline against which treatment response can be measured.

Medical history matters just as much. Diabetes or prediabetes, hypertension, significant infection, osteoporosis risk, glaucoma, gastrointestinal disease, psychiatric history, kidney or heart disease, pregnancy, vaccination status and other immunosuppressive treatment can all influence the decision.

Relevant travel or residence history and other risk factors for infections such as Strongyloides should also be considered.

The complete medication list should be reviewed.

The question is not simply whether prednisone can make hair grow. It is whether systemic corticosteroid exposure is justified for this particular patient and whether there is a credible plan for what happens when prednisone is reduced or stopped.

Who Should Be Especially Cautious With Prednisone?

Additional caution is appropriate in patients with:

• Diabetes or poorly controlled blood sugar
• Significant hypertension
• Active or recurrent infection
• Osteoporosis or high fracture risk
• Glaucoma or significant eye disease
• Peptic ulcer or significant gastrointestinal disease
• Serious mood or psychiatric disorders
• Heart failure or significant fluid retention
• Kidney disease or electrolyte abnormalities
• Significant liver disease
• Pregnancy or plans for pregnancy
• Repeated recent corticosteroid exposure
• Use of other immunosuppressive medications
• Relevant risk factors for latent or parasitic infection

These conditions do not all represent absolute contraindications. They change the risk benefit calculation and may require additional monitoring or a different treatment strategy.

What Should Someone Ask Before Starting Prednisone?

Useful questions include:

• Why is systemic prednisone being recommended instead of local treatment?
• Is my alopecia areata actively progressing?
• What is the objective of this course: stopping progression, producing regrowth or both?
• Are we using daily treatment or pulse treatment, and why?
• How long is the course expected to last?
• Will the dose be tapered, and is the taper primarily for disease control, adrenal safety or both?
• What should I do if hair loss begins again during the taper?
• What treatment will be used to try to maintain the response after prednisone?
• Do any of my medical conditions make systemic corticosteroids more risky?
• Could prednisone affect my blood pressure, blood sugar or potassium?
• Are there medications or vaccines I need to discuss before starting?
• Does my travel or exposure history raise concern for an infection that prednisone could worsen?
• What mood, sleep or infection symptoms should prompt a call to the physician?
• If I respond, how will we document whether the benefit persists after treatment ends?
• Would an FDA approved JAK inhibitor or another longer term strategy make more sense for my disease?

The answers should be individualized rather than based on a standard corticosteroid protocol applied to every patient with alopecia areata.

The AHLA Perspective

Oral prednisone remains a legitimate and sometimes very useful treatment for alopecia areata.

Its value is easiest to understand in a patient whose disease is highly active and progressing rapidly. Systemic corticosteroids can suppress autoimmune activity quickly and may stop further progression while allowing susceptible follicles to resume growth.

The fact that prednisone works, however, does not make it an ideal long term treatment.

The fundamental limitation has been recognized for decades. Some patients experience impressive regrowth only to begin losing hair again as the medication is reduced or discontinued. Maintaining the result by repeatedly increasing or continuing systemic corticosteroids can expose a patient to progressively greater medical risk.

This is why the goal should not be to use enough prednisone to keep the hair growing indefinitely.

Modern treatment has also changed the context. FDA approved JAK inhibitors now provide longer term systemic options for appropriately selected patients with severe alopecia areata. Local corticosteroid treatment remains highly useful for limited disease. Oral prednisone occupies an important space between those approaches, particularly when rapid short term systemic disease suppression is needed.

There is also no single universally accepted oral corticosteroid regimen for alopecia areata. Current international guidelines differ in whether they favor a daily tapering course or intermittent pulse treatment. That uncertainty should be acknowledged rather than presenting one dose schedule as though it were an FDA established standard.

The modern evidence also reinforces the importance of a maintenance strategy. Topical therapy, steroid sparing systemic treatment and FDA approved systemic therapies may all play a role depending on the patient. Prednisone should generally be used with an understanding of what will happen when systemic corticosteroid exposure ends.

Most importantly, prednisone should not be prescribed simply because someone is losing hair.

The diagnosis comes first. The extent and activity of alopecia areata matter. The patient’s medical risk matters. And before the first dose is taken, there should be a plan for what happens when systemic corticosteroid treatment ends.

The objective is to control active autoimmune disease with the lowest reasonable cumulative corticosteroid exposure, preserve viable follicles, document the response objectively and transition to a safer sustainable strategy when ongoing treatment is necessary.

Used for: Alopecia Areata

Selected References

1. Harries MJ, Ahmed A, Ascott A, et al. British Association of Dermatologists Living Guideline for Managing People With Alopecia Areata 2025. British Journal of Dermatology. 2026;194:e56-e73. British Journal of Dermatology
2. Blume-Peytavi U, Constantinou A, Tomova-Simitchieva T, et al. S3 Guideline Diagnostics and Therapy in Alopecia Areata, Part 2: Therapy, Psychosocial and Cosmetic Support. J Dtsch Dermatol Ges. 2026;24:e1155-e1177. doi:10.1111/ddg.70130x. PubMed
3. U.S. National Library of Medicine. Prednisone Tablets: Prescribing Information. Includes systemic corticosteroid warnings involving infection, Strongyloides, adrenal suppression, metabolic effects, vaccination, ophthalmic complications and drug interactions. DailyMed Prescribing Information
4. Olsen EA, Carson SC, Turney EA. Systemic Steroids With or Without 2% Topical Minoxidil in the Treatment of Alopecia Areata. Arch Dermatol. 1992;128:1467-1473. doi:10.1001/archderm.1992.01680210045005. PubMed
5. Kar BR, Handa S, Dogra S, Kumar B. Placebo-Controlled Oral Pulse Prednisolone Therapy in Alopecia Areata. J Am Acad Dermatol. 2005;52:287-290. doi:10.1016/j.jaad.2004.10.873. PubMed
6. Joly P, Lafon A, Houivet E, et al. Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patients With Alopecia Areata Totalis or Universalis: A 2-Step Double-Blind Randomized Clinical Trial. JAMA Dermatology. 2023;159:403-410. doi:10.1001/jamadermatol.2022.6687.
7. European Society of Endocrinology and Endocrine Society. Diagnosis and Therapy of Glucocorticoid-Induced Adrenal Insufficiency. 2024. Endocrine Society Clinical Practice Guideline
8. Centers for Disease Control and Prevention. Altered Immunocompetence: General Best Practice Guidelines for Immunization. CDC
9. MotherToBaby. Prednisone/Prednisolone. Updated May 2026. MotherToBaby
10. U.S. National Library of Medicine. Prednisone. Drugs and Lactation Database, LactMed. LactMed